Guggenheim lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $77 from $78 and keeps a Buy rating on the shares. The firm is updating estimates following the Q4 report, noting that SpringWorks’ pipeline is on track with initial Ogsiveo data in OvGCT coming in the first half of 2025 and an IND for new asset SW-3431 by year-end.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWTX:
- SpringWorks Therapeutics Reports Strong 2024 Performance
- SpringWorks Therapeutics reports FY24 EPS ($3.48), consensus ($3.16)
- SpringWorks, Jennifer Fisher team to increase understanding of desmoid tumors
- Springworks Therapeutics (SWTX) Q4 Earnings Cheat Sheet
- SpringWorks Therapeutics price target raised to $87 from $65 at BofA